Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL research hub

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This clinical trial is testing a medicine called selinexor for adults with diffuse large B-cell lymphoma (DLBCL). It is designed for people whose cancer has returned or stopped responding to prior treatments. Doctors want to see how well selinexor shrinks tumours and controls the disease safely.